Evidence map›Paper›PMID 25446948›Full record

ReviewNeuroscience and biobehavioral reviews2015

Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Kentaro Hirao, Gregory M Pontone, Gwenn S Smith

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience and biobehavioral reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The Noradrenergic System in Parkinson's Disease.Frontiers in pharmacology · 2020
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Molecular Imaging of the Nicotinic Cholinergic Receptor in Alzheimer Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2017
    Article
  14. Review
  15. Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Kentaro HiraoDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA; Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.
Gregory M PontoneDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA.
Gwenn S SmithDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA. Electronic address: gsmith95@jhmi.edu.
Johns Hopkins Medicine · US

Funding

Longitudinal Molecular Imaging of Neuropathology and Serotonin in Mild Cognitive ImpairmentR01AG059390 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2018 to 2022
$4.8M
Geriatric Depression: PET Studies of Pathophysiology and Treatment ResponseR01MH086881 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2010 to 2013
$2.7M
Longitudinal imaging of neuropsychiatric symptoms in mild cognitive impairmentR01AG041633 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2011 to 2015
$2.6M
PET Studies of Serotonin and Amyloid in MCIR01AG038893 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2011 to 2014
$2.4M
Anxiety in Parkinson's: Use of quantitative methods to guide rational treatmentK23AG044441 · NIA · JOHNS HOPKINS UNIVERSITY · PI PONTONE, GREGORY MICHAEL · 2014 to 2018
$1.0M
NIA NIH HHS AG038893NIA NIH HHS AG041633NIA NIH HHS K23 AG044441NIA NIH HHS K23AG044441NIA NIH HHS R01 AG038893NIA NIH HHS R01 AG041633NIA NIH HHS R01 AG059390NIMH NIH HHS R01 MH 086881NIMH NIH HHS R01 MH086881
6 · The paper itself

Abstract

Neuropsychiatric symptoms (NPS) are very common in neurodegenerative diseases and are a major contributor to disability and caregiver burden. There is accumulating evidence that NPS may be a prodrome and/or a "risk factor" of neurodegenerative diseases. The medications used to treat these symptoms in younger patients are not very effective in patients with neurodegenerative disease and may have serious side effects. An understanding of the neurobiology of NPS is critical for the development of more effective intervention strategies. Targeting these symptoms may also have implications for prevention of cognitive or motor decline. Molecular brain imaging represents a bridge between basic and clinical observations and provides many opportunities for translation from animal models and human post-mortem studies to in vivo human studies. Molecular brain imaging studies in Alzheimer's disease (AD) and Parkinson's disease (PD) are reviewed with a primary focus on positron emission tomography studies of NPS. Future directions for the field of molecular imaging in AD and PD to understand the neurobiology of NPS will be discussed.

Indexed as

Alzheimer DiseaseBrainHumansMolecular ImagingParkinson DiseaseAcetylcholineAlzheimer's diseaseDopamineMolecular imagingNeuropsychiatric symptomsParkinson's diseasePositron emission tomographySerotonin

Identifiers

PMID25446948
PMCPMC4806385
OpenAlexW2074224911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.